Our research group focuses on antimicrobial resistance and the optimization of antimicrobial therapy in clinical practice. A key area of interest is the development and evaluation of strategies for antimicrobial stewardship and antimicrobial policy, aimed at improving clinical outcomes and limiting the emergence of resistance.
Within this framework, there is a specific focus on translational research into biofilm-associated infections, such as periprosthetic joint infection, in which experimental models and clinical data are combined to develop new treatment strategies and optimize existing therapies.
The research encompasses clinical epidemiology, clinical trials and translational approaches, and makes use of data-driven analyses, including large clinical datasets. Within the epidemiological domain, Staphylococcus aureus bacteremia and other forms of bloodstream infection represent important areas of focus, aiming to improve understanding of disease course, treatment strategies and clinical outcomes.
This integrated approach enables the evaluation and refinement of treatment strategies within the context of both individual patient care and broader healthcare systems.
The group operates within a multidisciplinary and international network and contributes to clinical guidelines, policy development, and the further substantiation of rational antimicrobial use
